Metastatic renal cell carcinoma.
Metastatic renal cell carcinoma.
复制标题
DOI：
10.1007/s11864-003-0039-2
复制
发表时间：
2003-10-01
影响因子：
4.3
通讯作者：
Picken, Maria M
中科院分区：
文献类型：
--
作者：
Flanigan, Robert C;Campbell, Steven C;Picken, Maria M
肾细胞癌（RCC）患者在大约33%的病例中发生转移性扩散。由于缺乏有效的治疗方法，转移性肾细胞癌患者的临床管理变得复杂。常见的转移部位包括肺、肝、骨、脑和肾上腺，病例报告详细说明了RCC几乎可以出现在身体的任何地方。转移过程通常涉及不止一个器官系统。转移可能在诊断时或在肾切除术后的一段时间内发现。大约20%到50%的患者在肾切除术后最终会发展为转移性疾病。较短的时间间隔的肾脏切除术和发展转移与预后较差。转移性RCC患者预后不佳，中位生存期仅为6 - 12个月，2年生存率为10% - 20%。生物反应修饰剂疗法的最新进展为一小部分对该疗法有反应的患者带来了新的希望，并重新激起了人们对细胞减少性肾切除术作为这些患者治疗不可或缺的一部分的兴趣。
Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process. Metastases may be found at diagnosis or at some interval after nephrectomy. Approximately 20% to 50% of patients will eventually develop metastatic disease after nephrectomy. A shorter interval between nephrectomy and the development of metastases is associated with a poorer prognosis. Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%. Recent advances in biologic response modifier therapy have brought new hope to a small percentage of patients who respond to this therapy and rekindled interest in cytoreductive nephrectomy as an integral part of the management of these patients.